Preparation and Characterization of Chitosan Coated PLGA Nanoparticles of Resveratrol: Improved Stability, Antioxidant and Apoptotic Activities in H1299 Lung Cancer Cells
Source abstract
Abstract
Resveratrol (RES) is a polyphenolic compound which has shown beneficial pharmacological effects such as anti-inflammatory, antioxidant, and anti-cancer effects. However, poor aqueous solubility, bioavailability, and low stability are the major limitations to the clinical application of RES. Therefore, in the present study, chitosan (CS) coated PLGA nanoparticles of RES (CS-RES-PLGA NPs) was developed, characterized and its anticancer activity was evaluated in the H1299 lung carcinoma cell line. The effects of the increase in CS coating and cryoprotectant concentration on particle size, polydispersity index (PDI) and zeta potential (ZP) were determined. The particle size, PDI, ZP and entrapment efficiency of the optimized CS-RES-PLGA NPs were found to be 341.56 ± 7.90 nm, 0.117 ± 0.01, 26.88 ± 2.69 mV and 75.13% ± 1.02% respectively. The average particle size and ZP showed a steady increase with an increase in CS concentration. The increase in positive zeta potential is evident for higher CS concentrations. The effect of trehalose as cryoprotectant on average particle size was decreased significantly (p < 0.05) when it was increased from 1%−5% w/v. TEM and SEM showed uniform particle distribution with a smooth surface and spherical shape. The CS coating provides modulation of in vitro drug release and showed a sustained release pattern. The stability of RES loaded PLGA NPs was improved by CS coating. CS-coated NPs showed greater cytotoxicity and apoptotic activities compared to free RES. The CS coated NPs had a higher antioxidant effect than the free RES. Therefore, CS coated PLGA NPs could be a potential nanocarrier of RES to improve drug solubility, entrapment, sustain release, stability and therapeutic application.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Sirtuins and Resveratrol in Medicine · RNA Interference and Gene Delivery · Toxin Mechanisms and Immunotoxins
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia
Department of Biotechnology, Jamia Millia Islamia (Central University), New Delhi 110025, India
Funding
King Abdulaziz University
References (48)
Show source-provided references
1. Administration of resveratrol: What formulation solutions to bioavailability limitations?10.1016/j.jconrel.2011.09.083 ↗
2. Bioavailability of encapsulated resveratrol into nanoemulsion-based delivery systems10.1016/j.foodchem.2013.09.088 ↗
3. Neuroprotective properties of resveratrol and derivatives10.1111/j.1749-6632.2010.05865.x ↗
4. Ha, E.S., Sim, W.Y., Lee, S.K., Jeong, J.S., Kim, J.S., Baek, I.H., Choi, D.H., Park, H., Hwang, S.J., and Kim, M.S. (2019). Preparation and evaluation of resveratrol-loaded composite nanoparticles using a supercritical fluid technology for enhanced oral and skin delivery. Antioxidants, 8.10.3390/antiox8110554 ↗
5. Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase
6. High absorption but very low bioavailability of oral resveratrol in humans10.1124/dmd.104.000885 ↗
7. Rising horizon in circumventing multidrug resistance in chemotherapy with nanotechnology10.1016/j.msec.2019.04.005 ↗
8. Cell death pathway induced by resveratrol-bovine serum albumin nanoparticles in a human ovarian cell line10.3892/ol.2015.2851 ↗
9. Anticancer activity of resveratrol-loaded gelatin nanoparticles on NCI-H460 non-small cell lung cancer cells10.1016/j.bionut.2012.10.009 ↗
10. Wang, W., Zhang, L., Chen, T., Guo, W., Bao, X., Wang, D., Ren, B., Wang, H., Li, Y., and Wang, Y. (2017). Anticancer Effects of Resveratrol-Loaded Solid Lipid Nanoparticles on Human Breast Cancer Cells. Molecules, 22.10.3390/molecules22111814 ↗
11. Resveratrol-loaded PLGA nanoparticles mediated programmed cell death in prostate cancer cells10.1016/j.jsps.2018.03.009 ↗
12. Stimuli-responsive chitosan-based nanocarriers for cancer therapy10.15171/bi.2017.32 ↗
13. Miele, D., Catenacci, L., Sorrenti, M., Rossi, S., Sandri, G., Malavasi, L., Dacarro, G., Ferrari, F., and Bonferoni, M.C. (2019). Chitosan oleate coated poly lactic-glycolic acid (PLGA) nanoparticles versus chitosan oleate self-assembled polymeric micelles, loaded with resveratrol. Mar. Drugs, 17.10.3390/md17090515 ↗
14. Development of novel cationic chitosan- and anionic alginate–coated poly(D,L-lactide-co-glycolide) nanoparticles for controlled release and light protection of resveratrol
15. Surface engineering of resveratrol to improve neuro-protection and functional recovery after spinal cord injury in rat10.1016/j.jddst.2018.10.016 ↗
16. Controlling the in vitro release profiles for a system of haloperidol-loaded PLGA nanoparticles10.1016/j.ijpharm.2007.06.011 ↗
17. Md, S., Alhakamy, N.A., Aldawsari, H.M., and Asfour, H.Z. (2019). Neuroprotective and antioxidant effect of naringenin-loaded nanoparticles for nose-to-brain delivery. Brain Sci., 9.10.3390/brainsci9100275 ↗
18. Hyaluronic acid-modified betamethasone encapsulated polymeric nanoparticles: Fabrication, characterisation, in vitro release kinetics, and dermal targeting10.1007/s13346-018-0480-1 ↗
19. Delivery of curcumin by a pH-responsive chitosan mesoporous silica nanoparticles for cancer treatment10.1080/21691401.2017.1290648 ↗
20. Resveratrol-loaded PLGA nanoparticles: Enhanced stability, solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy10.1098/rsos.181457 ↗
21. Effect of nanoencapsulation using PLGA on antioxidant and antimicrobial activities of guabiroba fruit phenolic extract10.1016/j.foodchem.2017.07.144 ↗
22. Alhakamy, N.A., and Shadab, M. (2019). Repurposing itraconazole loaded PLGA nanoparticles for improved antitumor efficacy in non-small cell lung cancers. Pharmaceutics, 11.10.3390/pharmaceutics11120685 ↗
23. Synergistic anticancer activity of combined use of caffeic acid with paclitaxel enhances apoptosis of non-small-cell lung cancer H1299 cells in vivo and in vitro10.1159/000492253 ↗
24. Lu, B., Lv, X., and Le, Y. (2019). Chitosan-modified PLGA nanoparticles for control-released drug delivery. Polymers, 11.10.3390/polym11020304 ↗
25. Optimization and characterization of artesunate-loaded chitosan-decorated poly(D,L-lactide-co-glycolide) acid nanoparticles10.1155/2015/674175 ↗
26. Surface modification of PLGA nanoparticles using chitosan: Effect of molecular weight, concentration, and degree of deacetylation10.1002/adv.22077 ↗
27. Effect of cryoprotection on particle size stability and preservation of chitosan nanoparticles with and without hyaluronate or alginate coating10.1016/j.jsps.2016.12.008 ↗
28. Freeze-drying of nanoparticles: Formulation, process and storage considerations10.1016/j.addr.2006.09.017 ↗
29. A pilot study of freeze drying of poly(epsilon-caprolactone) nanocapsules stabilized by poly(vinyl alcohol): Formulation and process optimization10.1016/j.ijpharm.2005.10.003 ↗
30. Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles10.1016/S0378-5173(01)00944-9 ↗
31. Freeze thaw: A simple approach for prediction of optimal cryoprotectant for freeze drying10.1208/s12249-010-9382-3 ↗
32. Storage stabilisation of albumin-loaded chitosan nanoparticles by lyoprotectants
33. Chitosan nanoparticles: Preparation, size evolution and stability10.1016/j.ijpharm.2013.07.034 ↗
34. In vitro-in vivo evaluation of chitosan-PLGA nanoparticles for potentiated gastric retention and anti-ulcer activity of diosmin10.2147/IJN.S213836 ↗
35. Al-Nemrawi, N., Alshraiedeh, N., Zayed, A., and Altaani, B. (2018). Low molecular weight chitosan-coated PLGA nanoparticles for pulmonary delivery of tobramycin for cystic fibrosis. Pharmaceuticals, 11.10.3390/ph11010028 ↗
36. Polyethylene glycol on stability of chitosan microparticulate carrier for protein10.1208/s12249-010-9512-y ↗
37. Neves, A.R., Martins, S., Segundo, M.A., and Reis, S. (2016). Nanoscale delivery of resveratrol towards enhancement of supplements and nutraceuticals. Nutrients, 8.10.3390/nu8030131 ↗
38. Stability of trans-resveratrol encapsulated in a protein matrix produced using spray drying to UV light stress and simulated gastro-intestinal digestion10.1111/1750-3841.13176 ↗
39. Acidic tumor microenvironment and pH-sensing G protein-coupled receptors10.3389/fphys.2013.00354 ↗
40. MTT assay to evaluate the cytotoxic potential of a drug10.3329/bjp.v12i2.30892 ↗
41. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics10.1038/bjc.1972.33 ↗
42. Fan, Y., Chiu, J.-F., Liu, J., Deng, Y., Xu, C., Zhang, J., and Li, G. (2018). Resveratrol induces autophagy-dependent apoptosis in HL-60 cells. BMC Cancer, 18.10.1186/s12885-018-4504-5 ↗
43. Targeting the apoptosis pathway in hematologic malignancies10.3109/10428194.2013.855307 ↗
44. Glaucocalyxin A induces G2/M cell cycle arrest and apoptosis through the PI3K/Akt pathway in human bladder cancer cells10.7150/ijbs.23602 ↗
45. Hallmarks of cancer: The next generation10.1016/j.cell.2011.02.013 ↗
46. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G(2)-M arrest, and apoptosis
47. Resveratrol causes WAF-1/p21-mediated G1-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells
48. Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/p21 WAF1/CIP1 and p27 KIP1 pathway10.18632/oncotarget.15303 ↗